Abstract
Previously, we have shown that 30 min after S-(6-purinyl)-L-cysteine (PC; 0.13 or 0.4 mmol/kg, ip) treatment of rats, kidney concentrations of 6-mercaptopurine (6-MP) and its further metabolites, 6-methylmercaptopurine and 6-thiouric acid, were nearly 2.4-fold higher than those in liver, and were nearly 90-fold higher than those in plasma. 6-MP was also detected in the urine of rats given the PC analogs, S-(6-purinyl)-N-acetyl-L-cysteine (NAPC), S-(6-purinyl)glutathione (PG), and S-(6-purinyl)-L-homocysteine (PHC). In this study, the kidney-selectivity of the PC analogs was investigated by determining the concentrations of 6-MP and its further metabolites in the kidney, liver, and plasma of rats given the analogs. After NAPC, PG, and PHC (0.8 mmol/kg, ip) treatments, kidney concentrations of total metabolites at 30 min were nearly 17.6-, 6.5-, and 2.9-fold higher than those in liver, respectively. Only trace amounts of metabolites were detected in plasma with any analog. After NAPC treatment (0.8 mmol/kg, ip) total metabolite concentrations in the kidney at 30 min were higher than those detected at 60 or 90 min. When the PC analogs were given at a lower dose (0.4 mmol/kg), only trace amounts of metabolites were detected in the kidney, and no metabolites were detected in liver or plasma. Rates of in vitro metabolism of PHC, PG, and NAPC to 6-MP by kidney homogenates were nearly 10.0, 6.7, and 0.3% of that measured with PC, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|